IL33 and melanoma: Another study using a B16.OVA melanoma model revealed that systemically delivered IL-33 in combination with dectin-1-activated BM-derived DCs promoted PD-1 expression in OVA-specific CD4+ T cells, suggesting modulation of PD-1 levels in T cells via DC stimulation [199].